Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Takes Option to Commercialize Axis-Shield's HBP Sepsis Marker

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Axis-Shield said today that it has signed an agreement with Bio-Rad Laboratories for an option to commercialize heparin binding protein as a marker of severe sepsis.

Under the terms of this agreement, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments globally.

Additional terms of the deal were not disclosed.

Axis-Shield said that preliminary studies evaluating HBP's ability to detect sepsis have shown "improved specificity and sensitivity compared to existing methods."

Bio-Rad and Axis-Shield previously signed a similar agreement for Axis-Shield's anti-CCP technology for the early detection of rheumatoid arthritis.

That test, which measures anti-cyclic citrullinated peptide antibodies and runs on Bio-Rad's BioPlex 2200 system, was cleared by the US Food and Drug Administration last October.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.